Month: September 2020

BOCA RATON, FL, Sept. 09, 2020 (GLOBE NEWSWIRE) — Stem Holdings, Inc. (“Stem”) (OTCQX: STMH CSE: STEM), a leading vertically-integrated cannabis and hemp branded products company with state-of-the-art cultivation, processing, extraction, retail, and distribution operations throughout the United States, announced today the grand opening of its first dispensary in the Commonwealth of Massachusetts, Rebelle, in partnership with Community Growth Partners (CGP), a women-and minority-owned business, on Thursday, September 10, 2020.The new 3,600 square foot dispensary located at 783 South Main Street, Great Barrington, MA in the Berkshires, was designed and constructed with a team lead by Charlotte Hanna, founder of CGP. It has been purposely designed and built for a personal shopping experience with a knowledgeable and engaged staff,...

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challengeBNT162b2 immunization prevented lung infection in 100% of the SARS-CoV-2 challenged rhesus macaques, with no viral RNA detected in the lower respiratory tract of immunized and challenged animals. The BNT162b2 vaccination also cleared the nose of detectable viral RNA in 100% of the SARS-CoV-2 challenged rhesus macaques within 3 days after the infectionThe BNT162b2 vaccine candidate induced SARS-CoV-2 neutralizing antibodies in rhesus macaques, pseudovirus neutralizing antibodies in mice, and strong antigen-specific CD4+ and CD8+ T cells in mice and macaquesNEW YORK and MAINZ, Germany, Sept....

Die Immunisierung von nicht-humanen Primaten (Rhesusaffen) mit BNT162b2, einem nukleosidmodifizierten messenger RNA (modRNA)-Impfstoffkandidaten der für ein SARS-CoV-2-Spike-Glykoprotein kodiert, führte in einem infektiösenSARS-CoV-2-Challenge-Modell zu starken antiviralen EffektenDie Immunisierung mit BNT162b2 verhinderte in einem SARS-CoV-2-Challenge-Modell in 100% der Rhesusaffen eine Lungeninfektion. In den geimpften und anschließend infizierten Tieren konnte im unteren Bereich der Atemwege keine virale RNA detektiert werden. Die Impfung mit BNT162b2 sorgte ebenfalls dafür, dass 3 Tage nach einer Infektion mit SARS-CoV-2 bei keinem der Rhesusaffen mehr virale RNA in der Nase nachgewiesen werden konnte Der BNT162b2-Impfstoffkandidat induzierte in Rhesusaffen die Bildung neutralisierender Antikörper sowie in Mäusen die Bildung neutralisierender...

O opaganib inibiu completamente a replicação viral do SARS-CoV-2, conforme medido após três dias de incubação em um modelo in vitro de tecido brônquico humano, comparando favoravelmente com remdesivir, o controle positivo no estudo—O opaganib está posicionado exclusivamente como um tratamento potencial de COVID-19 administrado oralmente, combinando mecanismos de ação antivirais e anti-inflamatórios potentes, visando um componente da célula hospedeira e minimizando a probabilidade de resistência—Estudos clínicos de Fase 2/3 Global e Fase 2 dos EUA em andamento com opaganib para tratamento de pneumonia grave por COVID-19 —O segundo candidato ao medicamento para COVID-19 da RedHill, RHB-107 (upamostat), um novo inibidor de serina protease, inibiu fortemente a replicação viral de SARS-CoV-2 no mesmo modelo, apoiando ainda...

Opaganib inhibió completamente la replicación viral del SARS-CoV-2, según su medición después de tres días de incubación en un modelo in vitro de tejido bronquial humano, comparando favorablemente con remdesivir, el control positivo en el estudio—Opaganib está posicionado exclusivamente como un tratamiento para el COVID-19 administrado por vía oral, combinando mecanismos de acción antiviral y antiinflamatoria, direccionado a un componente de célula huésped y minimiza la probabilidad de resistencia—Estudios clínicos de Fase 2/3 globales y de Fase 2 de EUA en curso con opaganib para el tratamiento de neumonía grave por COVID-19 —El segundo candidato a fármaco para COVID-19 de RedHill, RHB-107 (upamostat), un inhibidor innovador de proteasa serina, inhibió fuertemente la replicación viral del SARS-CoV-2 en el mismo modelo,...

Drilling in central portion of Saddle Zone intersects broad zone of high-grade mineralization, confirms continuity of mineralized structure between Main and West pitsº Key intercepts: 1.10 grams per tonne (“gpt”) over 142.0 meters (“m”), including 9.39 gpt over 2.0 m, 2.15 gpt over 16.0 m, 1.23 gpt over 12.0 mDrilling in west portion of Saddle Zone intersects mineralization up to 420 m below West Pit reserve shellº Key intercepts: 1.80 gpt over 58.5 m, including 5.76 gpt over 2.8 m and 19.29 gpt over 2.0 m; 2.02 gpt over 38.1 m; 2.39 gpt over 29.0 m, including 11.57 gpt over 2.8 m and 10.01 gpt over 2.0 m; 1.47 gpt over 39 m; 1.40 gpt over 26.6 m, including 8.04 gpt over 2.0 m; 1.39 gpt over 25.5 m, including 8.74 gpt over 2.0 m; 1.51 gpt over 18.7 m, including 8.87 gpt over 2.0 m Drilling in eastern portion of Saddle Zone intersects...

MANITOWOC, Wis., Sept. 09, 2020 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of LED lighting systems and turnkey project implementation, including installation and commissioning of fixtures, controls and IoT capabilities, ongoing system maintenance and program management, will participate at H.C. Wainwright’s 22nd Annual Global Investment Conference to be held in a virtual format on Monday, September 14, 2020. Orion’s CEO Mike Altschaefl and CFO Bill Hull will participate at the event.H. C. Wainwright & Co., LLC is a full-service investment bank dedicated to providing Investment Banking, Equity Research, Sales & Trading as well Corporate Access and Strategic Advisory services.  The H.C. Wainwright Virtual 22ndAnnual Global Investment Conference will feature leading Greentech...

ROCHESTER, Mich., Sept. 09, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, providers and patients, has been invited to participate in two investor conferences being held in September.Event: H.C. Wainwright’s 22nd Annual Global Investment ConferenceDate: September 14-16, 2020Format: 1×1 meetings and live company presentationWebcast date and time: September 16th at 1:00 p.m. EDTWebcast link: click herePlease contact your H.C. Wainwright institutional sales representative for registration information.Event: Lake Street Capital Markets’ 4th Annual Best Ideas Growth (BIG4) ConferenceDate: September 17, 2020Format: 1×1 meetingsPlease contact your Lake Street institutional sales representative for registration information.OptimizeRx management...

WASHINGTON, Sept. 09, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Rick Arrowsmith as a Senior Managing Director in the Corporate Finance & Restructuring segment, adding to the depth of the firm’s healthcare restructuring offering.Mr. Arrowsmith specializes in turnaround and restructuring advisory, with a focus on sub-acute care, senior living, laboratory companies, medical equipment and life sciences. Based in Washington, D.C., he brings nearly 25 years of creditor workout experience and will work with the global FTI Consulting platform to advise clients in the healthcare sector as they navigate restructuring situations.“Rick is a leading restructuring specialist in the healthcare industry,” said Timothy Dragelin, a Senior Managing Director and Co-Leader of Healthcare Restructuring...

REDWOOD CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 22nd Annual Global Investment Conference. The conference, which will take place September 14-16, 2020, is being conducted with a virtual format.Dr. Goldsmith’s presentation will take place at 11:00 a.m. Eastern on Monday, September 14, 2020.  A live webcast of the presentation will be available. To access the live webcast of the presentation, please visit the “Events & Presentations” page within the Investors section of Revolution...